Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jbe who wrote (805)	3/14/2000 10:38:00 PM
From: Mike McFarland	Read Replies (3) \| Respond to of 52153

Maybe sort for revenue per employee, still beating the idea that you have to have specific reasons for owning a set of biotech companies. Message 13197771 Valuation is tricky in biotech, but maybe that means that the extra homework can pay off because there tend to be stocks which are incorrectly valued by the market.

To: jbe who wrote (805)	3/15/2000 12:38:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

jbe: You said that you don't want to read the thread. You're lazy, and that's fine. However, if you read this thread and a few others, you'd find that there's a gaggle of very informed contributors here who have been documenting their picks for years. Mike fits in great, as one of our many data-gathering freaks, with a serious collection of molecular biologists, organic chemists, neurologists, immunologists, etc. Biotech's best investors have clearly come from among our ranks. You can continue with this "how the hell could anybody tell which stocks will be winners?" crap, or you can do the homework to find that we've done such, with documentation. If you want to be noisy, that's fine. If you want to be lazy, fine again. But, if you want to be both noisy and lazy, would you mind finding some tech thread? Thanks. Rick